Characteristics, treatment patterns and survival of patients with high-risk early hormone receptor-positive breast cancer in French real-world settings: an exploratory study of the CANTO cohort.

Fiche publication

Date publication

novembre 2024

Journal

ESMO open

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BERTAUT Aurélie

Tous les auteurs :
Giugliano F, Bertaut A, Blanc J, Martin AL, Gaudin C, Fournier M, Kieffer A, Sauterey B, Levy C, Campone M, Tarpin C, Lerebours F, Mouret-Reynier MA, Curigliano G, André F, Pistilli B, Rassy E

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/39612621

Résumé

Patients with hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer (HR+ BC) with unfavorable features have an increased risk of relapse and are currently candidate for additional treatment strategies. We evaluated the real-world clinicopathological characteristics, treatment patterns and survival outcomes of these patients within the CANcer TOxicities study (CANTO, NCT01993498).